Donaldson acquires Isolere Bio

21-Feb-2023 - Last updated on 21-Feb-2023 at 15:04 GMT

Related tags Chromatography Filtration purification function sanitize_gpt_value2(gptValue) { var vOut = ""; var aTags = gptValue.split(','); var reg = new RegExp('\\W+', "g"); for (var i=0; i

Aimed initially at the purification of viral vectors used for cell and gene therapies, IsoTag reagents are designed to ‘substantially improve product quality and purity with faster timelines compared to competing solutions, enabling accelerated and more affordable delivery of life-changing therapies to patients globally’.

Founded in 2017 by Kelli Luginbuhl, Ph.D, Professor Ashutosh Chilkoti, and Joe McMahon, Isolere is headquartered in Durham, North Carolina.

Donaldson Company - a provider of filtration products and solutions for a range of industries and markets headquartered in Minneapolis - says the acquisition will help it tap into growth areas in the pharmaceutical industry.

It follows the 2021 acquisition of Italian company Solaris​​, which designs and manufactures bioprocessing equipment including bioreactors, fermenters and tangential flow filtration systems for use in food and beverage, biotech and other life science markets.

And in 2022, it acquired US biotech Purilogics, which leverages a novel technology platform for the development of membrane chromatography products (its purification tools are for a wide range of biologics, including mRNA, plasmid DNA, viral particles, monoclonal antibodies and proteins).

“With the integral addition of Isolere to our Life Sciences portfolio, Donaldson is positioned to create premier separation and filtration solutions for emerging genetic-based drugs,”​ said Tod Carpenter, chairman, president and chief executive officer of Donaldson. “We look forward to accelerating Isolere’s growth trajectory through sales synergies from our recent acquisitions of Solaris Biotechnology and Purilogics and through the strength of our balance sheet.”​

“Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere. “Our technology, complemented by Donaldson’s filtration excellence, is part of a larger vision to bring end-to-end solutions to the life sciences industry.”

Once commercialized, revenue from Isolere will be reported within the Donaldson Life Sciences segment.

Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Related topics Downstream Processing Analytical (technologies & services) Bioreactors Separation & Purification